Kalaris Therapeutics, Inc. — Investor Relations & Filings

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate, TH103, is a fully humanized, recombinant fusion protein designed for intravitreal delivery. Engineered to be a best-in-class anti-VEGF agent, TH103 acts as a soluble decoy receptor against Vascular Endothelial Growth Factor (VEGF). It possesses a high affinity for both VEGF and heparan sulfate proteoglycans (HSPG), which are believed to act as molecular anchors. This mechanism is designed to extend the therapy's intraocular retention, potentially reducing the frequency of injections for patients. The discovery of TH103 was led by scientific co-founder Dr. Napoleone Ferrara, a key scientist in the development of prior leading anti-VEGF drugs.